AKT1 and non-small cell lung carcinoma: Reactivation of the PI3K-AKT-mTOR and RAS-RAF-MEK pathways is the main resistance mechanism that is targeted BRAF V600E-mutant NSCLC therapy (Tabbo et al., 2022).